Could an old transplant drug help beat brain cancer?
NCT ID NCT07605364
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether adding mycophenolate mofetil, a drug usually used in organ transplants, to standard radiation and chemotherapy can help people with advanced glioblastoma live longer. About 422 participants will receive either the standard treatment or standard treatment plus mycophenolate mofetil. The goal is to see if the combination slows tumor growth and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mycophenolate mofetil
What this could lead to
If it works, this could extend survival for people with advanced glioblastoma by making standard treatments more effective.
What could go wrong
This is an early phase II/III trial, so results are uncertain. Adding mycophenolate mofetil may increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••